Medistim Management

Management criteria checks 3/4

Medistim's CEO is Kari Krogstad, appointed in Sep 2009, has a tenure of 14.58 years. total yearly compensation is NOK7.21M, comprised of 42% salary and 58% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth NOK12.35M. The average tenure of the management team and the board of directors is 9.3 years and 2 years respectively.

Key information

Kari Krogstad

Chief executive officer

kr7.2m

Total compensation

CEO salary percentage	42.0%
CEO tenure	14.6yrs
CEO ownership	0.4%
Management average tenure	9.3yrs
Board average tenure	2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kari Krogstad's remuneration changed compared to Medistim's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	kr7m	kr3m	kr104m
Sep 30 2023	n/a	n/a	kr117m
Jun 30 2023	n/a	n/a	kr116m
Mar 31 2023	n/a	n/a	kr116m
Dec 31 2022	kr9m	kr3m	kr114m
Sep 30 2022	n/a	n/a	kr98m
Jun 30 2022	n/a	n/a	kr92m
Mar 31 2022	n/a	n/a	kr93m
Dec 31 2021	kr6m	kr3m	kr91m
Sep 30 2021	n/a	n/a	kr88m
Jun 30 2021	n/a	n/a	kr84m
Mar 31 2021	n/a	n/a	kr70m
Dec 31 2020	kr6m	kr3m	kr69m
Sep 30 2020	n/a	n/a	kr71m
Jun 30 2020	n/a	n/a	kr74m
Mar 31 2020	n/a	n/a	kr75m
Dec 31 2019	kr4m	kr3m	kr70m
Sep 30 2019	n/a	n/a	kr79m
Jun 30 2019	n/a	n/a	kr73m
Mar 31 2019	n/a	n/a	kr64m
Dec 31 2018	kr4m	kr2m	kr57m
Sep 30 2018	n/a	n/a	kr46m
Jun 30 2018	n/a	n/a	kr48m
Mar 31 2018	n/a	n/a	kr45m
Dec 31 2017	kr4m	kr2m	kr48m

Compensation vs Market: Kari's total compensation ($USD653.61K) is about average for companies of similar size in the UK market ($USD760.97K).

Compensation vs Earnings: Kari's compensation has been consistent with company performance over the past year.

CEO

Kari Krogstad (59 yo)

14.6yrs

Tenure

kr7,205,702

Compensation

Ms. Kari Eian Krogstad serves as Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President. Ms. Krogst...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Kari Krogstad	CEO & President	14.6yrs	kr7.21m	0.39% NOK 12.4m
Thomas Jakobsen	Chief Financial Officer	no data	kr2.77m	0.17% NOK 5.3m
Helge Borslid	Vice President of Operations & Manufacturing	no data	kr1.67m	no data
Hæge Johanne Wetterhus	Vice President of Marketing	13.7yrs	kr1.87m	0.0087% NOK 278.5k
Hakon Grothe	Chief Innovation Officer	5yrs	kr1.91m	0.043% NOK 1.4m
Ole Eiksund	Chief Business Development Officer	2yrs	kr1.68m	0.032% NOK 1.0m
Mike Farbelow	President of Medistim USA Inc	no data	kr3.63m	0.011% NOK 348.4k
Roger Morberg	Vice President of Sales - APAC	no data	kr2.55m	0.089% NOK 2.8m
Stephanie Stenhagen	Vice President of Sales EMEA	no data	kr1.79m	0.015% NOK 487.2k
Ole Robsrud	Managing Director of Medistim Norge AS	no data	kr1.83m	0.019% NOK 602.2k

9.3yrs

Average Tenure

59yo

Average Age

Experienced Management: 0OCD's management team is seasoned and experienced (9.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Oyvin Broymer	Chairman	24.3yrs	kr495.00k	7.02% NOK 224.9m
Lars Ronn	Independent Director	14.3yrs	kr290.00k	0.014% NOK 438.4k
Anna Ahlberg	Independent Director	less than a year	no data	no data
Jon Hoem	Independent Director	1.3yrs	no data	no data
Ole Dahlberg	Independent Director	less than a year	no data	no data
Tove Raanes	Independent Director	10.3yrs	kr300.00k	no data
Anthea Arff-Pettersen	Director	2yrs	kr265.00k	no data

2.0yrs

Average Tenure

59yo

Average Age

Experienced Board: 0OCD's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Medistim Management

Management criteria checks 3/4

Key information

Recent management updates

Medistim ASA Announces Board Changes

Medistim ASA Announces Board Changes

CEO & President recently bought kr1.9m worth of stock

CEO & President recently sold kr10.0m worth of stock

Less than half of directors are independent

Independent Director recently bought kr301k worth of stock

Recent updates

Medistim ASA Approves Dividend for the Year 2023, Payable on May 6, 2024

Medistim ASA Announces Board Changes

Medistim ASA Announces Board Changes

Full year 2023 earnings released: EPS: kr5.68 (vs kr6.25 in FY 2022)

CEO & President recently bought kr1.9m worth of stock

Medistim ASA to Report Q1, 2024 Results on Apr 25, 2024

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

Third quarter 2023 earnings released: EPS: kr1.43 (vs kr1.35 in 3Q 2022)

Second quarter 2023 earnings released: EPS: kr1.80 (vs kr1.82 in 2Q 2022)

CEO & President recently sold kr10.0m worth of stock

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr1.41 (vs kr1.30 in 1Q 2022)

Upcoming dividend of kr4.50 per share at 1.7% yield

Independent Director recently bought kr301k worth of stock

Full year 2022 earnings released: EPS: kr6.25 (vs kr4.99 in FY 2021)

Danske Bank A/S acquired a 5% stake in Medistim ASA.

Medistim ASA to Report First Half, 2023 Results on Aug 31, 2023

Third quarter 2022 earnings released

Second quarter 2022 earnings released: EPS: kr1.82 (vs kr1.88 in 2Q 2021)

First quarter 2022 earnings released: EPS: kr1.30 (vs kr1.20 in 1Q 2021)

Upcoming dividend of kr3.75 per share

Full year 2021 earnings released: EPS: kr4.99 (vs kr3.81 in FY 2020)

Investor sentiment improved over the past week

Medistim ASA Proposes Ordinary Dividend for 2021, Payable on 9 May 2022

Investor sentiment deteriorated over the past week

Independent Director recently bought kr104k worth of stock

Medistim ASA Proposes Dividend

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorated over the past week

CEO & President recently bought kr4.4m worth of stock

Third quarter 2021 earnings released: EPS kr1.03 (vs kr0.79 in 3Q 2020)

Second quarter 2021 earnings released: EPS kr1.88 (vs kr1.11 in 2Q 2020)

Chief Financial Officer recently sold kr6.6m worth of stock

Medistim ASA Announces the Launch of the Pay Per Procedure Functionality to Latest MiraQTM Platform in the US Market

First quarter 2021 earnings released: EPS kr1.20 (vs kr1.16 in 1Q 2020)

Medistim ASA Approves Dividend, Payable on May 7, 2021

Full year 2020 earnings released: EPS kr3.81 (vs kr3.87 in FY 2019)

Chairman recently sold kr180m worth of stock

Universal-Investment-Luxembourg SA acquired a 5.07% stake in Medistim ASA (OB:MEDI).

Medistim ASA to Report First Half, 2021 Results on Aug 13, 2021

Medistim ASA Partners with Livanova PLC as Their New Distributor for India

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age